Skip to Content

CK12-01

Main Content

Optimal timing of allogeneic stem cell transplantation for chronic myeloid leukemia patients in the tyrosine kinase inhibitor era.

Study #: CK12-01

Study Status: Published

Presentation(s)

2017, ASH (Poster)

Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients.

Citation

Hu B, Lin X, Lee HC, Huang X, Tidwell RSS, Ahn KW, Hu Z-H, Jabbour E, Verstovsek S, Ravandi F, Garcia-Manero G, Kharfan-Dabaja MA, Hossain NM, Marks DI, Kamble RT, Inamoto Y, Kindwall-Keller T, Saad A, Litzow MR, Savani BN, Hale GA, Bacher U, Gerds AT, Liesveld JL, Ustun C, Olsson RF, Daly A, Grunwald MR, Solh M, DeFilipp Z, Aljurf M, Wirk B, Akpek G, Nishihori T, Cerny J, Seo S, Hsu JW, Champlin R, de Lima M, Alyea E, Popat U, Sobecks R, Scott BL, Kantarjian H, Cortes J, Saber W.

Leukemia & Lymphoma. 2020, Dec 01: 61(12): 61(12):2811-2820. doi: 10.1080/10428194.2020.1783444. Epub 2020, Jul 14. PMCID:PMC8424781.

PubMed

PMID: 32662346

Abstract